Skip to main content

99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping Over $250

Menu

Kynetide Research Team | 8 days ago

New Peptide Combination Shows Superior Weight Loss to Leading Obesity Drug Duo in Preclinical Study

A 2026 market-news look at Ascletis Pharma's ASC36_35 fixed-dose peptide combination, its preclinical weight-loss data against the eloralintide/tirzepatide combo, and what once-monthly amylin-GLP-1/GIP co-formulations could mean for the next generation of peptide-based obesity research.

New Peptide Duo Outperforms Rivals in Animal Obesity Model

Ascletis Pharma announced that preclinical data for ASC36_35 FDC, a once-monthly injectable co-formulation of two peptide drug candidates, will be presented in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan this fall. In a diet-induced obese rat model, the fixed-dose combination produced superior weight loss compared to eloralintide combined with tirzepatide, two of the most closely watched compounds in today's obesity-drug landscape. Jinzi Jason Wu, Ascletis' founder, chairman and CEO, said the data reflect the importance of advancing new treatment options for patients with obesity.

Inside ASC36_35: Two Peptides, Three Metabolic Targets

The ASC36_35 fixed-dose combination pairs ASC36, a peptide amylin-receptor agonist, with ASC35, a dual peptide agonist of the GLP-1 and GIP receptors, packaged into a single once-monthly subcutaneous injection. Ascletis describes the co-formulation as a potentially first-in-class candidate because it engages three validated metabolic targets, the amylin receptor, GLP-1R and GIPR, at once. The once-monthly dosing relies on the company's Self-Assembling Lipid Depot formulation, part of its proprietary Ultra-Long-Acting Platform, which is designed to slow-release peptide payloads over weeks rather than days.

A Crowded Race: 2026's Obesity Peptide Pipeline Keeps Accelerating

Ascletis' announcement lands in the middle of an unusually crowded year for obesity peptide research. A new State of Peptides 2026 report from the Peptide Alliance pegs the broader peptide market at $50 to $60 billion, with GLP-1 and related multi-receptor agonists cited as a primary growth driver, while Ascletis itself has spent 2026 advancing a stack of related programs, including ASC30, an oral small-molecule GLP-1R agonist, and ASC37, a triple GLP-1R/GIPR/GCGR peptide agonist. The pace reflects a broader industry pattern: as tirzepatide and other dual agonists become the benchmark to beat, companies are increasingly pairing peptides that hit different metabolic receptors in a single formulation to chase incremental gains in weight loss.

Why Purity and Verified Sourcing Still Matter as the Pipeline Accelerates

Preclinical peptide combinations like ASC36_35 are still years away from any pharmacy shelf, and Ascletis' data are limited to an animal model presented at a scientific meeting, not a clinical trial in humans. But the steady drumbeat of new multi-receptor peptide candidates underscores how fast the underlying science is moving, and how much research demand there is for well-characterized amylin, GLP-1 and GIP peptide analogs to study receptor behavior, formulation stability and combination effects. For labs working with these compound classes, that only raises the importance of starting from documented, third-party-verified material. Every peptide Kynetide lists ships with a batch-specific Certificate of Analysis confirming 99%+ HPLC purity, and every product is intended strictly for laboratory research use, not for human or animal administration.

FAQ: Is ASC36_35 Available for Purchase or Clinical Use?

Not yet, and not for some time. The data Ascletis is presenting come from a diet-induced obese rat model, not a human trial, and the findings will be discussed at EASD's Annual Meeting in Milan this fall. Ascletis has already secured FDA IND clearance for related programs, including ASC36 as a standalone injection, but ASC36_35 as a fixed-dose combination remains in earlier-stage development. Any path to approval would still require completing the standard phases of human clinical testing before the combination could reach patients.

FAQ: Does This News Affect How I Should Source Research Peptides?

It reinforces it. Whether or not multi-receptor combinations like ASC36_35 eventually reach the clinic, the underlying research categories, amylin analogs, GLP-1/GIP dual agonists, and long-acting peptide formulations, are exactly the compound classes labs are studying right now. Kynetide's role isn't to speculate on which pipeline candidate will win; it's to make sure researchers working in this space have documented, third-party-verified starting material. Every peptide we offer ships with a batch-specific Certificate of Analysis confirming 99%+ HPLC purity, and our products are intended strictly for laboratory research, not for human or animal use, dosing, or self-administration.

Let’s create what matters — together.

Kynetide Research Team

More Posts

How to Read a Peptide COA: A Researcher's Guide to Certificates of AnalysisHow to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis
How to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

Jul 31 | Kynetide Research Team
Peptide Reconstitution 101: Bacteriostatic Water, Dilution Math & StoragePeptide Reconstitution 101: Bacteriostatic Water, Dilution Math & Storage
Peptide Reconstitution 101: Bacteriostatic Water, Dilution Math & Storage

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Jul 30 | Kynetide Research Team
How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)
How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

Jul 30 | Kynetide Research Team
What's Really in Your Compounded GLP-1?What's Really in Your Compounded GLP-1?
What's Really in Your Compounded GLP-1?

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

Jul 29 | Kynetide Research Team
Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide VotePatient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote
Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

Jul 29 | Kynetide Research Team
The Peptide Safety Gap Nobody's Watching Is at Your Local Med SpaThe Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa
The Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

Jul 28 | Kynetide Research Team
The Peptide Headlines Don't Match the PaperworkThe Peptide Headlines Don't Match the Paperwork
The Peptide Headlines Don't Match the Paperwork

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

Jul 28 | Kynetide Research Team
Six Peptides In, One Rejected: What the FDA Vote Really ChangesSix Peptides In, One Rejected: What the FDA Vote Really Changes
Six Peptides In, One Rejected: What the FDA Vote Really Changes

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

Jul 27 | Kynetide Research Team
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar MarketFDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.

Jul 26 | Kynetide Research Team